ConductScience.org, home

Paper41004518

Anti-cancer compound screening identifies Aurora Kinase A inhibition as a means to favor CRISPR/Cas9 gene correction over knock-out.

Wilbie D and 8 others. PLoS One, 2025. Cited by 1 paper, by iCite.

Cite this record

ConductScience Library. Anti-cancer compound screening identifies Aurora Kinase A inhibition as a means to favor CRISPR/Cas9 gene correction over knock-out. Papers, record 41004518. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/41004518

Download JSON
Sources
11 sources
Release
papers-2026-11-12-0.1.0

Paper

PubMed's record of the paper, with iCite's citation figures. No abstract is shown.

Title
Anti-cancer compound screening identifies Aurora Kinase A inhibition as a means to favor CRISPR/Cas9 gene correction over knock-out.
PubMed
Journal
PLoS One
PubMed
Year
2025
PubMed
Publication types
Journal Article, Research Support, Non-U.S. Gov't
PubMed
Citations, by iCite
1
iCite
Revised in PubMed
2026-10-23
PubMed

Authors9

The authors in the order PubMed's record lists them, with the ORCID iDs it states.

OrderAuthorForenameKindORCID iD
1Wilbie DDannyhttps://orcid.org/0000-0003-1004-304X
2Eising SSelma
3Amo-Addae VVicky
4Walther JJohanna
5Bosman EEsmeralda
6Lei ZZhiyong
7de Jong OGOlivier G
8Molenaar JJJan J
9Mastrobattista EEnrico

Source PubMed

Download CSV of authors

Topics13

NLM's MeSH indexing of the paper, its major topics first.

MeSH termMajor
CRISPR-Cas SystemsMajor topic
Aurora Kinase AMajor topic
Antineoplastic AgentsMajor topic
Protein Kinase InhibitorsMajor topic
Humans
HEK293 Cells
Gene Knockout Techniques
Gene Editing
Pyrimidines
Drug Screening Assays, Antitumor
Recombinational DNA Repair
Cell Line, Tumor
Azepines

Source PubMed

Download CSV of topics

Grants1

Each grant PubMed's record writes, matched to the NIH project NIH's grant and paper links name for this paper, and each of those links the record does not write.

Grant, as the record writes itAgencyCountryNIH projectStated by
865.17.005Netherlands Organisation for Scientific Research (NWO) Talent program VICIPubMed

Source PubMed

Download CSV of grants

References42

The papers the reference list in PubMed's record names, those in our copy of PubMed, in the list's order.

OrderPMIDTitleJournalYearIn PapersSource
130944467Precise therapeutic gene correction by a simple nuclease-induced double-stranded break.Nature2019https://conductscience.org/library/papers/30944467PubMed
229538768Easy quantification of template-directed CRISPR/Cas9 editing.Nucleic Acids Res2018https://conductscience.org/library/papers/29538768PubMed
33663476A study of some variables in a tetrazolium dye (MTT) based assay for cell growth and chemosensitivity.Br J Cancer1987https://conductscience.org/library/papers/3663476PubMed
429804829Kinetics and Fidelity of the Repair of Cas9-Induced Double-Strand DNA Breaks.Mol Cell2018https://conductscience.org/library/papers/29804829PubMed
526437586Repair Pathway Choices and Consequences at the Double-Strand Break.Trends Cell Biol2016https://conductscience.org/library/papers/26437586PubMed
631178391Editing the Sickle Cell Disease Mutation in Human Hematopoietic Stem Cells: Comparison of Endonucleases and Homologous Donor Templates.Mol Ther2019https://conductscience.org/library/papers/31178391PubMed
731099553Delivery Aspects of CRISPR/Cas for in Vivo Genome Editing.Acc Chem Res2019https://conductscience.org/library/papers/31099553PubMed
826612622Exosomes from hypoxic endothelial cells have increased collagen crosslinking activity through up-regulation of lysyl oxidase-like 2.J Cell Mol Med2016https://conductscience.org/library/papers/26612622PubMed
930189348The influence of eukaryotic chromatin state on CRISPR-Cas9 editing efficiencies.Curr Opin Biotechnol2019https://conductscience.org/library/papers/30189348PubMed
1020382844A novel Aurora-A kinase inhibitor MLN8237 induces cytotoxicity and cell-cycle arrest in multiple myeloma.Blood2010https://conductscience.org/library/papers/20382844PubMed
1128177771Precision genome editing in the CRISPR era.Biochem Cell Biol2017https://conductscience.org/library/papers/28177771PubMed
1240242216CRISPR-dependent base editing as a therapeutic strategy for rare monogenic disorders.Front Genome Ed2025https://conductscience.org/library/papers/40242216PubMed
1328939824In trans paired nicking triggers seamless genome editing without double-stranded DNA cutting.Nat Commun2017https://conductscience.org/library/papers/28939824PubMed
1429490262A Single Administration of CRISPR/Cas9 Lipid Nanoparticles Achieves Robust and Persistent In Vivo Genome Editing.Cell Rep2018https://conductscience.org/library/papers/29490262PubMed
1538191764Extracellular vesicle-mediated delivery of CRISPR/Cas9 ribonucleoprotein complex targeting proprotein convertase subtilisin-kexin type 9 (Pcsk9) in primary mouse hepatocytes.J Extracell Vesicles2024https://conductscience.org/library/papers/38191764PubMed
1626458548Highly efficient CRISPR/HDR-mediated knock-in for mouse embryonic stem cells and zygotes.Biotechniques2015https://conductscience.org/library/papers/26458548PubMed
1732207531Gene editing and CRISPR in the clinic: current and future perspectives.Biosci Rep2020https://conductscience.org/library/papers/32207531PubMed
1840373211Patient-Specific In Vivo Gene Editing to Treat a Rare Genetic Disease.N Engl J Med2025https://conductscience.org/library/papers/40373211PubMed
1930687381Methodologies for Improving HDR Efficiency.Front Genet2018https://conductscience.org/library/papers/30687381PubMed
2028512351Non-homologous DNA end joining and alternative pathways to double-strand break repair.Nat Rev Mol Cell Biol2017https://conductscience.org/library/papers/28512351PubMed

See all 42 referencesDownload CSV of references

Cited by3

The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 1 citation.

PMIDTitleJournalYearIn PapersSource
42300182Azide-functionalized SpCas9 enables generation of site-selective and bioactive Cas9-siRNA conjugates.Chem Commun (Camb)2026https://conductscience.org/library/papers/42300182PubMed
40674218Protocol to rapidly screen CRISPR-Cas9 gene editing outcomes in a cell population by mutating eGFP to a blue or non-fluorescent phenotype.STAR Protoc2025https://conductscience.org/library/papers/40674218PubMed
40533769Aurora kinases signaling in cancer: from molecular perception to targeted therapies.Mol Cancer2025https://conductscience.org/library/papers/40533769PubMed

Download CSV of cited by

Genes5

The genes the Gene search release ties to the paper: Swiss-Prot's references first, then PubTator's text mining.

GeneNCBI Gene IDLinked byIn GenesSource
AURKA6790PubTator's text mininghttps://conductscience.org/library/genes/6790NCBI Gene
LIG43981PubTator's text mininghttps://conductscience.org/library/genes/3981NCBI Gene
PARP1142PubTator's text mininghttps://conductscience.org/library/genes/142NCBI Gene
PARP210038PubTator's text mininghttps://conductscience.org/library/genes/10038NCBI Gene
RAD515888PubTator's text mininghttps://conductscience.org/library/genes/5888NCBI Gene

Download CSV of genes

Data dates

The date of each source this release read.

PubMed
2026-11-06
PubMed
iCite
2026-11-05
iCite
PMC's ID file
2026-11-05
PMC's ID file
NIH RePORTER's grant and paper links
2026-11-01
NIH RePORTER's grant and paper links
Trials
2026-11-12
Gene search
2026-11-11
Pipelines
2026-09-18

None in this release

  • Trials
  • Comments and corrections
  • Drugs
  • Data

Sources 11

  • ChEMBL, through Open TargetsCC BY-SA 3.0
  • ClinicalTrials.govNo license stated
  • HGNCCC0
  • iCiteCC BY 4.0
  • NCBI GenePublic domain (US government)
  • NIH RePORTER's grant and paper linksPublic domain
  • Open TargetsCC0 1.0
  • PMC's ID filePublic domain (US government)
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0
Each source's terms
  • ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • ClinicalTrials.govnone stated
  • HGNCCC0: https://www.genenames.org/about/license/
  • iCiteCC BY 4.0
  • NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
  • NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
  • Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this paper from software.

The record and each of its lists are JSON, twenty rows a page. No key.

GET https://conductscience.org/api/papers/v1/41004518

GET https://conductscience.org/api/papers/v1/41004518/references?page=2